Axa S.A. Lava Therapeutics Nv Transaction History

Axa S.A.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.59 - $3.97 $2,755 - $6,880	-1,733 Reduced 0.76%	225,748 $374,000
Q4 2022 Feb 14, 2023	SELL	$3.37 - $7.31 $4,010 - $8,698	-1,190 Reduced 0.52%	227,481 $796,000
Q3 2022 Feb 14, 2023	BUY	$2.34 - $4.75 $2,803 - $5,690	1,198 Added 0.53%	228,671 $548,000
Q3 2022 Nov 14, 2022	BUY	$2.34 - $4.75 $2,803 - $5,690	1,198 Added 0.53%	228,671 $1.05 Million
Q2 2022 Feb 14, 2023	SELL	$2.28 - $4.4 $10,061 - $19,417	-4,413 Reduced 1.9%	227,473 $671,000
Q2 2022 Aug 15, 2022	SELL	$2.28 - $4.4 $10,061 - $19,417	-4,413 Reduced 1.9%	227,473 $671,000
Q1 2022 Feb 14, 2023	BUY	$4.28 - $6.55 $13,760 - $21,058	3,215 Added 1.41%	231,886 $1.02 Million
Q1 2022 May 13, 2022	BUY	$4.28 - $6.55 $8 - $13	2 Added 0.0%	231,886 $1.02 Million
Q4 2021 Feb 14, 2022	BUY	$4.23 - $7.77 $11,687 - $21,468	2,763 Added 1.21%	231,884 $1.28 Million
Q3 2021 Nov 15, 2021	BUY	$5.5 - $11.0 $46,519 - $93,038	8,458 Added 3.83%	229,121 $1.36 Million
Q2 2021 Aug 13, 2021	BUY	$10.8 - $16.0 $3,240 - $4,800	300 Added 0.14%	220,663 $2.4 Million
Q1 2021 May 14, 2021	BUY	$12.5 - $15.19 $2.75 Million - $3.35 Million	220,363 New	220,363 $3.35 Million

3.61M

32.9K

500

Ticker LVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,797,700
Market Cap $26.8M
Description
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.